Controlled Substances Act

The DEA has initiated an administrative hearing to reclassify marijuana as a Schedule III substance under the Controlled Substances Act, which would facilitate research but not alter criminal penalties or mandatory minimums.

The Drug Enforcement Administration is considering rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act, which would classify cannabis products as having accepted medical use. The article argues this move lacks scientific evidence and criticizes policymakers for prioritizing politics over science.

States debate stricter THC limits on cannabis products amid research linking high-potency cannabis to increased risks of psychosis and cannabis use disorder, particularly among adolescents and young adults. A Connecticut mother shares her son's decline after using cannabis for social anxiety, highlighting the challenges of addiction and mental health impacts.

High-potency cannabis products are fueling state debates over risks of psychosis and addiction, particularly among adolescents and young adults. States are considering stricter THC limits as research links frequent use of high-THC cannabis to mental health issues. A Connecticut mother shared her son’s decline after cannabis use led to cannabis use disorder and psychotic episodes.

States debate stricter THC limits for cannabis products amid research linking high-potency cannabis to increased risks of psychosis and addiction, particularly among adolescents. A Connecticut mother shares her son's experience developing cannabis use disorder after using high-THC products, highlighting erratic behavior and mental health decline.

High-potency cannabis products are fueling debates over psychosis and addiction risks, with states considering stricter THC limits. A Connecticut mother describes her son's decline after cannabis use led to severe mental health issues and cannabis use disorder, highlighting growing concerns about the health impacts of legal, high-THC products.

High-potency cannabis products are fueling state debates over psychosis and addiction risks, with some lawmakers proposing stricter THC limits. A Connecticut mother describes her son's decline due to cannabis use disorder, highlighting concerns about mental health impacts, particularly among adolescents. Research links frequent high-THC use to increased risks of psychosis and addiction, while federal reclassification of medical marijuana has raised questions about public perception.

States are debating stricter THC limits on cannabis products due to rising concerns over psychosis and addiction risks linked to high-potency cannabis. A Connecticut mother describes her son's severe cannabis use disorder and erratic behavior after using cannabis to cope with anxiety, highlighting broader public health concerns. Research suggests frequent use of high-THC cannabis increases mental health risks, particularly for adolescents and young adults.

A New Orleans man was found guilty of violating the federal Controlled Substances Act and the Federal Gun Control Act. The conviction was secured through a federal court proceeding.

The Trump administration reclassified cannabis from Schedule I to Schedule III under the Controlled Substances Act, signaling a shift in federal drug policy. This change, led by the U.S. Drug Enforcement Administration (DEA), aims to facilitate medical research and reduce legal barriers for cannabis-related businesses.

The Trump administration has reclassified marijuana from schedule I to schedule III under the Controlled Substances Act, aligning it with drugs like ketamine and steroids. Previously, marijuana was classified alongside heroin, LSD, and synthetic opioids. The change follows an executive order signed by Donald Trump over four months ago.